FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Petersen

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Richard C Becker; Kenneth W Mahaffey; Hongqiu Yang; A J Marian; Mark I Furman; A Michael Lincoff; Stanley L Hazen; John L Petersen; Craig J Reist; Neal S Kleiman
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.
John L Petersen; John J Barron; Bradley G Hammill; Mark J Cziraky; Kevin J Anstrom; Peter M Wahl; Eric L Eisenstein; Mitchell W Krucoff; Robert M Califf; Kevin Schulman; Lesley H Curtis
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database.
Sunil V Rao; John Eikelboom; Ph Gabriel Steg; A Michael Lincoff; William S Weintraub; Jean-Pierre Bassand; A Koneti Rao; C Michael Gibson; John L Petersen; Roxana Mehran; Steven V Manoukian; Richard Charnigo; Kerry L Lee; Mauro Moscucci; Robert A Harrington
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Petersen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Richard C Becker; Kenneth W Mahaffey; Hongqiu Yang; A J Marian; Mark I Furman; A Michael Lincoff; Stanley L Hazen; John L Petersen; Craig J Reist; Neal S Kleiman
Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.
Journal of thrombosis and thrombolysis 2011;31(2):146-53.
2010: John L Petersen; John J Barron; Bradley G Hammill; Mark J Cziraky; Kevin J Anstrom; Peter M Wahl; Eric L Eisenstein; Mitchell W Krucoff; Robert M Califf; Kevin Schulman; Lesley H Curtis
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database.
American heart journal 2010;159(3):462-470.e1.
2009: Sunil V Rao; John Eikelboom; Ph Gabriel Steg; A Michael Lincoff; William S Weintraub; Jean-Pierre Bassand; A Koneti Rao; C Michael Gibson; John L Petersen; Roxana Mehran; Steven V Manoukian; Richard Charnigo; Kerry L Lee; Mauro Moscucci; Robert A Harrington
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group.
American heart journal 2009;158(6):881-886.e1.
2009: Jeffrey S Berger; John L Petersen; David L Brown
Vascular disease burden and in-hospital outcomes among patients undergoing percutaneous coronary intervention in New York State.
Circulation. Cardiovascular interventions 2009;2(4):317-22.
2008: J Matthew Brennan; John L Petersen
Early intervention: which patients and how early?
Current cardiology reports 2008;10(4):303-11.
2008: Mitchell W Krucoff; Dean J Kereiakes; John L Petersen; Roxana Mehran; Vic Hasselblad; Alexandra J Lansky; Peter J Fitzgerald; Jyotsna Garg; Mark A Turco; Charles A Simonton; Stefan Verheye; Christophe L Dubois; Roger Gammon; Wayne B Batchelor; Charles D O'Shaughnessy; James B Hermiller; Joachim Schofer; Maurice Buchbinder; William Wijns
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
Journal of the American College of Cardiology 2008;51(16):1543-52.
2006: Harvey D White; Neal S Kleiman; Kenneth W Mahaffey; Yuliya Lokhnygina; Karen S Pieper; Karen Chiswell; Marc Cohen; Robert A Harrington; Derek P Chew; John L Petersen; Lisa G Berdan; Philip E G Aylward; Christopher C. Nessel; James J Ferguson; Robert M Califf
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
American heart journal 2006;152(6):1042-50.
2006: Jeffrey S Berger; John L Petersen; James E Tcheng; Harry R Phillips
Clinical implications of vulnerable plaque.
Future cardiology 2006;2(6):721-31.
2006: John L Petersen; Ghazala Haque; Anne S Hellkamp; Greg C Flaker; N A Mark Estes; Francis E Marchlinski; John H McAnulty; Arnold J Greenspon; Roger A Marinchak; Kerry L Lee; Gervasio A Lamas; Kenneth W Mahaffey
Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee.
Contemporary clinical trials 2006;27(3):260-8.
2006: Wael A Aljaroudi; John L Petersen
Obesity, diabetes, and associated risk factors.
Current treatment options in cardiovascular medicine 2006;8(1):67-78.
2005: Robert M Califf; John L Petersen; Vic Hasselblad; Kenneth W Mahaffey; James J Ferguson
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
American heart journal 2005;149(4 Suppl):S91-9.
2005: John L Petersen; Darren K McGuire
Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease 2005;2(1):9-15.
2004: John L Petersen; Kenneth W Mahaffey; Richard C Becker; Shaun G Goodman; Neal S Kleiman; A J Marian; Gregg W Stone; Alexandra J Lansky; A Michael Lincoff; Stanley L Hazen; Christopher C. Nessel; Luis Toro-Figueroa; Lynn Tate; Craig J Reist; Marc Cohen; Robert M Califf; James J Ferguson
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
American heart journal 2004;148(2):269-76.
2004: John L Petersen; Kenneth W Mahaffey; Vic Hasselblad; Elliott M Antman; Marc Cohen; Shaun G Goodman; Anatoly Langer; Michael A Blazing; Anne Le-Moigne-Amrani; James A de Lemos; Christopher C. Nessel; Robert A Harrington; James J Ferguson; Eugene Braunwald; Robert M Califf
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
JAMA : the journal of the American Medical Association 2004;292(1):89-96.
2004: Abhinav Goyal; John L Petersen; Kenneth W Mahaffey
The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes.
Current cardiology reports 2004;6(4):300-7.
2003: John L Petersen; Darren K McGuire; Robert A Harrington
Advances and continued controversy in coronary revascularization of patients with diabetes mellitus.
Current diabetes reports 2003;3(5):351-5.
2003: John L Petersen; Jean-Pierre Dery; Michael C Fischi; Adrian F Hernandez; Patrick M Hranitzky; Sunil V Rao; Abdallah G Rebeiz; Kanwar P Singh
Highlights from the American College of Cardiology Annual Scientific Sessions 2003: March 28 to April 2, 2003.
American heart journal 2003;146(1):19-26.
2003: Jean-Pierre Dery; Adrian F Hernandez; Joseph D Kay; John L Petersen; Sunil V Rao; Abdallah G Rebeiz; Kanwar P Singh; Mark P Donahue
Highlights from the American Heart Association annual scientific sessions 2002: November 17 to 20, 2002.
American heart journal 2003;145(3):554-62.